APA (7th ed.) Citation

Ruhnke, L., Röllig, C., Herold, S., Sauer, T., Brandts, C. H., Steffen, B., . . . Thiede, C. (2023). Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: Results of the SAL MIDOKIT trial : letter to the editor. Haematologica, 108(9), . https://doi.org/10.3324/haematol.2022.281636

Chicago Style (17th ed.) Citation

Ruhnke, Leo, et al. "Midostaurin in Addition to Intensive Chemotherapy in Acute Myeloid Leukemia with T(8;21) and KIT And/or FLT3- ITD Mutations: Results of the SAL MIDOKIT Trial : Letter to the Editor." Haematologica 108, no. 9 (2023). https://doi.org/10.3324/haematol.2022.281636.

MLA (9th ed.) Citation

Ruhnke, Leo, et al. "Midostaurin in Addition to Intensive Chemotherapy in Acute Myeloid Leukemia with T(8;21) and KIT And/or FLT3- ITD Mutations: Results of the SAL MIDOKIT Trial : Letter to the Editor." Haematologica, vol. 108, no. 9, 2023, https://doi.org/10.3324/haematol.2022.281636.